Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.

ABSTRACT:

Background

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) considers blood eosinophil counts < 100 cells/μL (BEC_≤100) in people with COPD to predict poor inhaled corticosteroid (ICS) responsiveness. However, the BEC_≤100 phenotype is inadequately characterized, especially in advanced COPD.

Research question

Are there differences between GOLD group D patients with high BEC and those with low BEC regarding baseline characteristics and longitudinal outcomes?

Study design and methods

We used multivariable mixed models and logistic regression to contrast clinical characteristics and outcomes of BEC_≤100 vs BEC > 100 (BEC₁₀₀₊) in all subjects with COPD (n = 1,414) and GOLD group D subjects (n = 185) not receiving ICS.

Results

We identified n = 485 with BEC_≤100 (n = 61 GOLD group D) and n = 929 people with BEC₁₀₀₊ (n = 124 GOLD group D). BEC_≤100 status was stable at 6 weeks and approximately 52 weeks (intraclass correlations of 0.78 and 0.71, respectively). Compared with BEC₁₀₀₊, BEC_≤100 comprised more women, with greater current smoking, and less frequent childhood asthma. Among all analyzed participants, the two BEC-defined subsets showed similar rates of lung function decline (mean slope, BEC_≤100 vs BEC₁₀₀₊, -50 vs -39 mL/y; P = .140), exacerbations (0.40 vs 0.36/y; P = .098), subsequent ICS initiation (2.5% vs 4.4%; P = .071), and mortality (7.8% vs 8.4%; P = .715). However, in GOLD group D, people with BEC_≤100 showed higher exacerbation rates within 365 days of enrollment (0.62 vs 0.33/y; P = .002) and total follow-up (1.16 vs 0.83/y; P = .014). They also had greater lung function decline (mean slope of -68 mL/y vs -23 mL/y; P = .036) and had greater emphysema at baseline (voxels < 950 Hounsfield units at total lung capacity of 7.46% vs 4.61%; P = .029).

Interpretation

In non-ICS-treated GOLD group D COPD, people with BEC_≤100 had more baseline emphysema, prospective exacerbations, and lung function decline. Our analysis has identified a particularly vulnerable subpopulation of people with COPD, suggesting the need for studies focused specifically on their therapeutic treatment.

Clinical trial registration

ClinicalTrials.gov; No.: NCT01969344; URL: www.

Clinicaltrials

gov.

SUBMITTER: LeMaster WB 

PROVIDER: S-EPMC10083128 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature